Japan introduced a new health coverage scheme for long-listed products (LLPs) on October 1. A survey of generic drug makers…
REGULATORY
New Scheme on Switch OTC Gets Underway
The Ministry of Health, Labor and Welfare (MHLW) launched a new panel on April 13 that would pick prescription drug candidates that should be switched to non-prescription status, marking the kickoff of a new switch OTC scheme amid doctors’ wariness…
To read the full story
Related Article
- MHLW Panel Rebuffs Nonprescription Switches of 3 PPIs
August 3, 2018
- Healthcare Experts at Odds over Nonprescription Switches of 3 PPIs
March 20, 2018
- MHLW Council Recommends Switching of 4 APIs; Switching of Levonorgestrel for Emergency Contraception Disapproved
July 28, 2017
- 6 APIs Added to List of “Switch OTC” Candidates: MHLW
June 26, 2017
- MHLW Announces 16 APIs as Candidates for Switch-OTC Status: None for Lifestyle Diseases
December 13, 2016
- MHLW to Launch Switch OTC Panel as Early as Summer
June 3, 2015
REGULATORY
- Supply of Anapeine Generic to Start by Year-End: Minister
October 9, 2024
- MHLW Issues Notification to Spur Use of RWD in Place of Clinical Trial Data
October 7, 2024
- New Health Minister to Stick to Honebuto Text on Off-Year Plan
October 7, 2024
- Ishiba Makes No Mention on Pharma in First Policy Speech
October 7, 2024
- Komeito’s Yoko Wanibuchi Newly Named Senior Vice Health Minister
October 4, 2024
It’s easy to spot motivated and engaged employees. They are more productive, they go the extra mile, and they display a sense of ownership in their work.But how do you replicate this culture throughout your organization? How do you encourage…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…